PMID- 28525532
OWN - NLM
STAT- MEDLINE
DCOM- 20171013
LR  - 20220330
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 147
IP  - 6
DP  - 2017 Jun 1
TI  - The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant 
      Assays: A Large, Retrospective Study at a Coagulation Reference Laboratory.
PG  - 632-640
LID - 10.1093/ajcp/aqx035 [doi]
AB  - OBJECTIVES: To investigate the effects of indirect- and direct-acting 
      anticoagulants on the interpretation of lupus anticoagulant (LAC) assays. 
      METHODS: A retrospective database review was performed to identify all LAC panels 
      from November 2012 to November 2015. The positivity rates for three LAC tests 
      were compared among various anticoagulant medications. RESULTS: This analysis 
      included 7,721 LAC panels. Direct oral anticoagulants, warfarin, and 
      unfractionated heparin (UFH) were associated with higher LAC positivity rates 
      compared with patients not receiving documented anticoagulation (83% for 
      argatroban, 58% for dabigatran, 72% for rivaroxaban, 53% for apixaban, 56% for 
      warfarin, and 36% for UFH vs 29% for no anticoagulation, P < .025). Direct 
      thrombin inhibitors mainly affected the activated partial thromboplastin 
      time-based assays and the tissue thromboplastin inhibition index (TTI), while 
      direct factor Xa inhibitors mainly affected the TTI and the dilute Russell viper 
      venom ratio. CONCLUSIONS: Results of LAC testing performed while patients are 
      receiving anticoagulant therapies should be interpreted with caution to avoid 
      misdiagnosing patients with the antiphospholipid syndrome and potentially 
      committing them to long-term anticoagulation therapy.
CI  - (c) American Society for Clinical Pathology, 2017. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com
FAU - Seheult, Jansen N
AU  - Seheult JN
AD  - From the Department of Pathology and.
FAU - Meyer, Michael P
AU  - Meyer MP
AD  - Coagulation Laboratory, Institute for Transfusion Medicine, Pittsburgh, PA.
FAU - Bontempo, Franklin A
AU  - Bontempo FA
AD  - Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh 
      School of Medicine, PA ; and.
AD  - Coagulation Laboratory, Institute for Transfusion Medicine, Pittsburgh, PA.
FAU - Chibisov, Irina
AU  - Chibisov I
AD  - From the Department of Pathology and.
AD  - Coagulation Laboratory, Institute for Transfusion Medicine, Pittsburgh, PA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*therapeutic use
MH  - Antiphospholipid Syndrome/blood/*diagnosis
MH  - Antithrombins/therapeutic use
MH  - Blood Coagulation Tests
MH  - Child
MH  - Child, Preschool
MH  - Factor Xa Inhibitors/therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Infant
MH  - Lupus Coagulation Inhibitor/*blood
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Retrospective Studies
MH  - Warfarin/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Direct oral anticoagulants
OT  - Direct thrombin inhibitor
OT  - Factor Xa inhibitor
OT  - Low molecular weight heparin
OT  - Lupus anticoagulant
OT  - Warfarin
OT  - unfractionated heparin
EDAT- 2017/05/20 06:00
MHDA- 2017/10/14 06:00
CRDT- 2017/05/20 06:00
PHST- 2017/05/20 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
PHST- 2017/05/20 06:00 [entrez]
AID - 3835436 [pii]
AID - 10.1093/ajcp/aqx035 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2017 Jun 1;147(6):632-640. doi: 10.1093/ajcp/aqx035.